masitinib + FOLFIRI

Masitinib + FOLFIRI is an investigational combination therapy being studied for the treatment of metastatic colorectal cancer. This regimen combines **masitinib**, an oral tyrosine kinase inhibitor targeting mast cell activity, with **FOLFIRI**, a standard intravenous chemotherapy protocol consisting of folinic acid (leucovorin), fluorouracil (5-FU), and irinotecan. Masitinib inhibits mast cell activation by blocking c-Kit and other tyrosine kinases, with the intent of reducing pro-tumorigenic inflammation, remodeling of the tumor microenvironment, and angiogenesis. FOLFIRI acts through cytotoxic mechanisms: irinotecan inhibits topoisomerase I, fluorouracil disrupts DNA synthesis, and folinic acid increases fluorouracil efficacy. The combination is explored in clinical trials as a second- or later-line therapy for patients with metastatic colorectal cancer who have progressed after first-line treatments[1][3][5][7][9].